NEJM Publishes Data from Study of Gene Therapy in Hemophilia B
The New England Journal of Medicine
has published interim data from Spark Therapeutics' Phase 1/2 clinical trial of SPK-9001 in patients with hemophilia B.
UW General Surgery Resident Explains T Cell Immunotherapy in Fibrolamellar Carcinoma
In this video, Kevin Sullivan, M.D., discusses why he and his group have an interest in this space, as well as what challenges he’s had in working with a rare cancer type.
Can Neratinib Be Effective in Rare Liver Cancer?
Richard Cutler of Puma Biotechnology is hopeful that neratinib, which was approved for breast cancer in July, can provide clinical benefit to rare liver cancers.
Primary Endpoints Met in Phase 3 of Imbruvica with Rituximab in Waldenstom's Macroglobulinemia
A Phase 3 of Imbruvica in combination with Rituxan in relapsed/refractory and treatment-naïve patients with Waldenstrom’s macroglobulinemia has successfully met its primary endpoint.
Praveen Sethupathy Explores the Fibrolamellar Space
Praveen Sethupathy, PhD sat down with
Rare Disease Report
to discuss why it’s worth being excited about the new breakthroughs being made in fibrolamellar carcinoma.
FDA Hands Amphivena Orphan Drug Designation for New Approach to AML
Amphivena Therapeutics, Inc. was granted Orphan Drug Designation from the U.S. FDA for AMV564, its lead compound intended for the treatment of Acute Myeloid Leukemia.
The Sickle Cell Association of New Jersey Talks Delayed Diagnosis and the Importance of Awareness
Rare Disease Report
sat down with Mary LaMar, founder and CEO of The Sickle Cell Association of America, and sickle cell disease patient Sakiyyah Darden who also works in an administrative support role for the organization.
Mogamulizumab's BLA Accepted for Filing and Priority Review Designation
The FDA has accepted for review the Biologics License Application for mogamulizumab to treat Cutaneous T-cell Lymphoma in patients who have received at least one prior systemic therapy.
FDA Grants Breakthrough Therapy Designation to PellePharm for Gorlin Syndrome Treatment
The FDA granted Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for its compound topical patidegib for use in patients with Basal-cell nevus syndrome (BCNNS).
Richard Bryce of Puma Biotechnology Talks Neratinib in Fibrolamellar
Richard Bryce of Puma Biotechnology discusses his company’s interest in neratinib and working with fibrolamellar cancer.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.